BioCentury
ARTICLE | Finance

Big news

Biotech names and milestones investors like heading into 2H15

July 13, 2015 7:00 AM UTC

The performance of big cap biotechs has lagged that of companies one tier down, but the second half includes a host of milestones that could put the bellwethers on a steeper upward trajectory.

Buysiders largely ignored the crop of PDUFA dates in 2Q15, but investors contacted by BioCentury have at least two regulatory milestones at the top of their watch lists this half. ...